Champions Oncology Inc

Champions Oncology reported first-quarter fiscal 2027 revenues of $15.2 million, up 8.8% from $13.9 million a year earlier, while its GAAP net loss narrowed to $426,000 from $466,000 and adjusted earnings per share rose to 5 cents from 1 cent. Within the company's single reportable oncology-services segment, pharmacology services revenues rose 6.9% to $14.2 million from $13.2 million, Translational Oncology Solutions data-license revenues jumped 187.1% to $893,000 from $311,000, and other TOS revenues declined 59.7% to $183,000 from $454,000. Oncology services margin improved to 51% from 43%, cost of oncology revenues fell 5.8% to $7.5 million, and adjusted EBITDA rose to $671,000 from $59,000, even as total costs and operating expenses increased 7.7% to $15.6 million. The company used $492,000 of cash in operating activities against $600,000 generated a year earlier, ended July with $4.4 million in cash, and said cash on hand plus expected operating cash flows should fund operations through at least September 2027. CEO Robert Brainin credited improved study execution and conversion in the core research-services business, and management said it continues talks with venture groups and potential pharmaceutical partners on outside funding or a licensing partnership for Corellia without giving a timetable, while providing no formal revenue or earnings guidance.

Champions Oncology reported record annual revenue of $59.4 million and full-year adjusted EBITDA of $1.6 million for fiscal 2026, with CEO Robert Brainin stating the company’s Corellia initiative is fully funded for fiscal 2027. Fourth-quarter revenue was $13.8 million, and adjusted EBITDA was $158,000, marking the fourth consecutive quarter of positive adjusted EBITDA. Services revenue reached a record $58.7 million, while data license revenue fell to approximately $800,000 from $4.7 million in fiscal 2025, which included a large one-time transaction. Gross margin improved to 51% in the fourth quarter from 41% a year earlier, helped by reduced outsourced radiopharmaceutical costs. The company ended the year with $4.9 million in cash and no debt, and management expects services growth to moderate while data revenue remains volatile, with some expected fourth-quarter recognition shifting into the first quarter of fiscal 2027.